HK Stock Market Move | VENUS MEDTECH-B(02500) rose more than 4%. The tricuspid valve replacement product, Cardiovalve, has formally submitted its application for EU CE certification.

VENUS MEDTECH-B (02500) rose by over 4%, at the time of writing, it has increased by 4.64%, reaching 2.48 Hong Kong dollars, with a trading volume of 1.1562 million Hong Kong dollars. On the news front, Venus Medtech announced that the group has recently submitted all application materials for CE MDR certification of the Cardiovalve transcatheter tricuspid valve replacement system (Cardiovalve system) to the European regulatory agency. This marks a critical step in the access process of the product in the European market. The Cardiovalve system is a transcatheter intervention replacement product that can be used to treat both mitral and tricuspid regurgitation. Compared to similar products, the Cardiovalve system's femoral vein access route significantly improves treatment safety. The product's large valve ring design of up to 55mm is suitable for approximately 95% of patients, and its unique short stent design effectively reduces the risk of left ventricular outflow tract obstruction. The Cardiovalve system is easy to operate, safe, and highly reproducible, requiring only three steps: positioning, anchoring, and release.